Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib +/- Degarelix in Early Prostate Cancer
NCT02324998Phase 1Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Dec 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olaparib in prostate cancer (PCa) (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Determination of PARP Inhibition at 2 weeks. Started Dec 2016; status: completed.
02
Drugs
olaparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02324998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02324998.